伊马替尼相关基因多态性与伊马替尼耐药  

Gene polymorphism and imatinib resistance

作　　者：高梅梅[1] 耿春梅[1] 史蕾[1] 郭瑞臣[1] 

机构地区：[1]山东大学齐鲁医院临床药理学研究所,山东济南250012

出　　处：《中国医院药学杂志》2016年第12期1037-1040,1042,共5页Chinese Journal of Hospital Pharmacy

摘　　要：伊马替尼属靶向小分子酪氨酸激酶抑制剂,为治疗慢性粒细胞白血病的一线药物,临床用其甲磺酸盐。随着其广泛应用,耐药也迅速产生。伊马替尼的耐药机制十分复杂,涉及多个基因、蛋白及信号传导通路的异常表达或改变。本文主要分析接受伊马替尼治疗的慢性粒细胞白血病患者相关基因的多态性与其耐药机制的关系,为实现慢性粒细胞白血病的合理有效治疗提供依据。Imatinib is a small molecular tyrosine kinase inhibitor,targeting for therapy against chronic myelogenous leukemia and used as a first line therapeutic agent.Imatinib mesylate is used in clinical practice.However resistances are observed followed by its extensive application and leads to therapeutic failures.Mechanisms involved in resistance of imatinib are very complex,including mutations of multiple genes,proteins and signaling pathways.In this paper,the relationship between gene polymorphism and imatinib resistance are disoussed to provide a basis for treating chronic myelogenous leukemia.

关 键 词：基因多态性 伊马替尼 慢性粒细胞白血病 耐药 

分 类 号：R968[医药卫生—药理学]